LIAN News and Press, LianBio From 05/09/22

Mavacamten demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers Study was conducted in parallel with ongoing Phase 3 EXPLORER-CN trial of mavacamten in obstructive hypertrophic cardiomyopathy to support regulatory approval in Chin...

SHANGHAI, China and PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) --  LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that management will participate in the Bank of America ...

SHANGHAI, China and PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- LianBio’s (Nasdaq: LIAN) partner, Tarsus Pharmaceuticals, Inc. (Tarsus) yesterday announced that TP-03 (lotilaner ophthalmic solution, 0.25%) met the primary endpoint and all secondary endpoints in the Saturn-2 piv...

Gainers: GTY Technology Holdings (GTYH) +114%. Vaxxinity (VAXX) +57%. Zymeworks (ZYME) +35%. Redbox Entertainment (RDBX) +33%. Finch Therapeutics Group (FNCH) +29%. Opiant Pharmaceuticals (OPNT) +29%. Puyi (PUYI) +27%. Cyngn (CYN) +24%. Clearwater (CLW) +24%. Anixa Biosciences (ANIX) +21%. Lo...

Shares of LianBio (NASDAQ:LIAN) are down 24% in Friday afternoon trading even as the company and partner Bristol-Myers Squibb (BMY) this morning won approval for the hypertrophic cardiomyopathy drug Camzyos (mavacamten). One of the reasons for the decline could be that the approval ...

Gainers: Finch Therapeutics (FNCH) +46%. Zymeworks (ZYME) +44%. Lantheus (LNTH) +13%. BeiGene (BGNE) +12%. Inari Medical (NARI) +11%. Losers: Accolade (ACCD) -55%. Aldeyra Therapeutics (ALDX) -15%. Venus Concept (VERO) -14%. Bio...

SHANGHAI and PRINCETON, N.J., April 29, 2022 (GLOBE NEWSWIRE) -- LianBio’s (Nasdaq: LIAN) partner, Bristol Myers Squibb, announced yesterday that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10 mg and 15 mg capsules) for the tre...

The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb' and LianBio (LIAN)'s Camzyos (mavacamten) to treat certain patients with a heart condition called hypertrophic cardiomyopathy. Camzyos — which was approved in 2.5 mg, 5 mg, 10 mg, 15 mg capsules ȁ...

LinkDoc has formally withdrawn its plan to raise $200 million from a U.S. IPO, nine months after its 11th hour halt to the listing. Three other Chinese companies with pending U.S. listings could revive their plans in the second half of this year as last year’s regulatory turmoi...

SHANGHAI, China and PRINCETON, N.J., April 14, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the formation and members of its Scientific Advisory Board (...